Chen Xiaohui1, L I Xin2, W U Dehua1. 1. Department of Radiotherapy, Nanfang Hospita, Department of Oncology, Southern Medical University, Guangzhou 510515, China. 2. Department of Radiotherapy, Department of Oncology, College of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Abstract
OBJECTIVE: To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC). METHODS: HCC cell lines SMMC-7721 and HCC-LM3 were transfected with an ETV4- overexpressing plasmid or small interfering RNAs (siRNAs) targeting ETV4. The cells with ETV4 overexpression or ETV4 interference were treated with DMSO, sorafenib (5 μmol/L) or cisplatin (5 μmol/L) for 48 h, and the total protein and total RNA were collected. Western blotting, flow cytometry, EdU proliferation assay were used to analyze the apoptosis and proliferation of the cells. We also obtained clinical specimens of HCC tissues and paired adjacent tissues from 11 patients for detecting ETV4 mRNA expression levels using real-time fluorescence quantitative PCR (q-PCR). The effect of ETV4 interference on the mRNA expression levels of immediate early response gene 3 (IER3) was examined in HCC cells that were treated with DMSO, sorafenib or cisplatin for 48 h. RESULTS: The expression of ETV4 mRNA was significantly higher in HCC tissues than in the paired adjacent tissues. Overexpression of ETV4 in the HCC cell lines obviously inhibited cell apoptosis induced by sorafenib or cisplatin. Conversely, ETV4 interference significantly enhanced the apoptosis and inhibited the proliferation of the HCC cells following treatments with sorafenib or cisplatin. In addition, ETV4 regulated the mRNA expression levels of IER3 in the cells treatmed with sorafenib and cisplatin. CONCLUSIONS: ETV4 promotes resistance of HCC cells to sorafenib or cisplatin in vitro.
OBJECTIVE: To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC). METHODS: HCC cell lines SMMC-7721 and HCC-LM3 were transfected with an ETV4- overexpressing plasmid or small interfering RNAs (siRNAs) targeting ETV4. The cells with ETV4 overexpression or ETV4 interference were treated with DMSO, sorafenib (5 μmol/L) or cisplatin (5 μmol/L) for 48 h, and the total protein and total RNA were collected. Western blotting, flow cytometry, EdU proliferation assay were used to analyze the apoptosis and proliferation of the cells. We also obtained clinical specimens of HCC tissues and paired adjacent tissues from 11 patients for detecting ETV4 mRNA expression levels using real-time fluorescence quantitative PCR (q-PCR). The effect of ETV4 interference on the mRNA expression levels of immediate early response gene 3 (IER3) was examined in HCC cells that were treated with DMSO, sorafenib or cisplatin for 48 h. RESULTS: The expression of ETV4 mRNA was significantly higher in HCC tissues than in the paired adjacent tissues. Overexpression of ETV4 in the HCC cell lines obviously inhibited cell apoptosis induced by sorafenib or cisplatin. Conversely, ETV4 interference significantly enhanced the apoptosis and inhibited the proliferation of the HCC cells following treatments with sorafenib or cisplatin. In addition, ETV4 regulated the mRNA expression levels of IER3 in the cells treatmed with sorafenib and cisplatin. CONCLUSIONS:ETV4 promotes resistance of HCC cells to sorafenib or cisplatin in vitro.
Authors: P Pawlikowska; I Leray; B de Laval; S Guihard; R Kumar; F Rosselli; F Porteu Journal: Cell Death Differ Date: 2010-05-14 Impact factor: 15.828
Authors: R Metzger; C G Leichman; K D Danenberg; P V Danenberg; H J Lenz; K Hayashi; S Groshen; D Salonga; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; B Konda; L Leichman Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Simon L Currie; Jedediah J Doane; Kathryn S Evans; Niraja Bhachech; Bethany J Madison; Desmond K W Lau; Lawrence P McIntosh; Jack J Skalicky; Kathleen A Clark; Barbara J Graves Journal: J Mol Biol Date: 2017-07-17 Impact factor: 5.469
Authors: M R Emma; J L Iovanna; D Bachvarov; R Puleio; G R Loria; G Augello; S Candido; M Libra; A Gulino; V Cancila; J A McCubrey; G Montalto; M Cervello Journal: Cell Death Dis Date: 2016-06-23 Impact factor: 8.469
Authors: Mandy Dumortier; Franck Ladam; Isabelle Damour; Sophie Vacher; Ivan Bièche; Nathalie Marchand; Yvan de Launoit; David Tulasne; Anne Chotteau-Lelièvre Journal: Breast Cancer Res Date: 2018-07-11 Impact factor: 6.466